1. J. Kao,D. Chen (2002). Global control of hepatitis B virus infection. Lancet Inectf. Dis, 2, 395-403.
2. M. Brunetto,F. Moriconi,F. Bonino,G. Lau,P. Farci,C. Yurdaydin,T. Piratvisuth,K. Luo,Y. Wang,S. Hadziyannis,E. Wolf,P. McCloud,R. Batrla,P. Marcellin (2009). Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †. Hepatology, 49, 1141-1150.
3. R. Moucari,V. Mackiewicz,O. Lada,M. Ripault,C. Castelnau,M. Martinot-Peignoux,A. Dauvergne,T. Asselah,N. Boyer,P. Bedossa,D. Valla,M. Vidaud,M. Nicolas-Chanoine,P. Marcellin (2009). Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients #. Hepatology, 49, 1151-1157.
4. H. Chan,V. Wong,A. Tse,C. Tse,A. Chim,H. Chan,G. Wong (2007). Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. Clinical Gastroenterology and Hepatology, 5(12), 1462-1468.
5. Resat Ozaras,Fehmi Tabak,Veysel Tahan,Recep Ozturk,Hakan Akin,Ali Mert,Hakan Senturk (2008). Correlation of Quantitative Assay of HBsAg and HBV DNA Levels During Chronic HBV Treatment. Digestive Diseases and Sciences, 53(11), 2995-2998.
6. G. Realdi,G. Fattovich,S. Hadziyannis,S. Schalm,P. Almasio,J. Sanchez-Tapiaas (1994). Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). Journal of Hepatology, 21(4), 656-666.
7. C. Chu,Y. Liaw (2007). HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow up.
8. A. Lok,B. McMahon (2009). AASLD Practice Guidelines. Chronic Hepatitis B: Update 2009. Hepatology, 50, 1-36.
9. R. Biswas,E. Tabor,C. Hsia,D. Wright,M. Laycock,E. Fiebig,L. Peddada (2003). Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion, 43(6), 788-798.
10. W. Gerlich,M. Kann (2005). Hepatitis B.in Topley Wilson’s Microbiology and Microbial Infections,9th Edition. Topley Wilson’s Microbiology and Microbial Infections, 1226-1268.
11. Timothy Block,Anand Mehta,Baruch Blumberg,Raymond Dwek (2006). Does Rapid Oligomerization of Hepatitis B Envelope Proteins Play a Role in Resistance to Proteasome Degradation and Enhance Chronicity?. DNA and Cell Biology, 25(3), 165-170.
12. W. Gerlich,R. Thomssen (1975). Standardidised detection of hepatitis B surface antigen; Determination of its serum concentration in weight units per volume. Dev Biol Stand, 30, 78-87.
13. H. Joller-Jemelka,H. Pfister,P. Grob (1985). The prognostic significance of quantitative HBsAG determination in acute hepatitis B. Schweiz Med Wochenschr, 115, 1249-1256.
14. B. Burczynska,K. Madalinski,J. Pawlawska (1994). The value of quantitative measurement of HBeAg and HBsAg before interferon-α treatment of chronic hepatitis B in children. Journal of Hepatology, 21(6), 1097-1102.
15. W. Gerlich,U. Wend,D. Glebe (2004). Quantitative Assay of Hepatitis B Surface Antigen in Serum or Plasma Using Laurell Electrophoresis. Methods Mol Med, 95, 57-63.
16. R. Karakus,L. Aral,B. Basturk,C. Aybay (2007). Development of a Highly Sensitive ELISA for Quantification of Hepatitis B Virus (HBV) Surface Antigen (HBsAg). Turk J Med Sci, 37, 87-92.
17. Johannes Wiegand,Heiner Wedemeyer,Andrea Finger,Benjamin Heidrich,Jens Rosenau,Gerd Michel,C. Bock,Michael Manns,Hans Tillmann (2008). A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels. Antiviral Therapy, 13(4), 547-554.
18. M. Brunetto,F. Oliveri,P. Colombatto,F. Moriconi,P. Ciccorossi,B. Coco (2010). Use of HBsAg serum levels help to distinguish active from inactive HBV genotype D carriers. Gastroenterology, 139, 483-490.
19. T. Nguyen,A. Thompson,S. Bowden,C. Croagh,S. Bell,P. Desmond,M. Levy,S. Locarnini (2010). Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol, 52, 508-1.
20. C. Chen,H. Yang,J. Su,C. Jen,S. You,S. Lu (2006). Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc, 295, 65-73.
21. U. Iloeje,H. Yang,J. Su,C. Jen,S. You,C. Chen (2006). Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. Gastroenterology, 130, 678-686.
22. J. Kim,J. Choi,S. Bae,S. Yoon,J. Yang,N. Han (2010). Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology, 8(1), 60-65.
23. R. Mukherjee,P. Balkumar Reddy,M. Sasikala (2009). Identification of genotype B among Hepatitis B Virus-infected patients in Hyderabad, India. Ann Hepatol, 8, 269-270.
24. H. Chan,A. Hui,V. Wong (2005). Long‐term follow‐up of peginterferon and lamivudine combination treatment in HBeAg‐positive chronic hepatitis B†. Hepatology, 41(6), 1357-1364.
25. J. Sung,M. Wong,S. Bowden (2005). Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy. Gastroenterology, 128(7), 1890-1897.
26. B. Lapostolle,S. Bowden,S. Locarnini (2004). Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 126, 1750-1758.
27. Uchenna Iloeje,Hwai–i. Yang,Chin–lan Jen,Jun Su,Li–yu Wang,San–lin You,Chien–jen Chen (2007). Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology, 5(8), 921-931.
28. Rathindra Mukherjee,P. Balkumar Reddy,J. Arava,P. Rao,M. Sasikala,R. Gupta,D. Reddy (2010). Relationship between serum HBsAg level, HBV DNA level, and peripheral immune cells in patients with chronic hepatitis B virus infection.